Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

29 recalls, newest first

Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0185-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 63868-480-24 D-0184-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 0363-0131-30 D-0183-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 11673-849-40 D-0179-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0178-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 71713-203-02 D-0177-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 43598-808-62 D-0176-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 30142-131-30 D-0174-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 69842-871-30 D-0173-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 30142-505-34 D-0172-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 49035-404-61 D-0171-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 0363-0010-34 D-0170-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Completed Nitrosamine impurity Dr. Reddy's Laboratories, Inc. D-0169-2020
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-03 D-0413-2019

Recalls by year